Nanobiotix SA
NBTX20.850USD
-0.190-0.90%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.01BMarket Cap
LossP/E TTM
More Details of Nanobiotix SA Company
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
Nanobiotix SA Info
Ticker SymbolNBTX
Company nameNanobiotix SA
IPO dateOct 29, 2012
CEOLevy (Laurent)
Number of employees108
Security typeDepository Receipt
Fiscal year-endOct 29
Address60 rue de Wattignies
CityPARIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code75012
Phone33140260470
Websitehttps://www.nanobiotix.com
Ticker SymbolNBTX
IPO dateOct 29, 2012
CEOLevy (Laurent)
Company Executives of Nanobiotix SA
Name
Name/Position
Position
Shareholding
Change
Dr. Laurent Levy, Ph.D.
Dr. Laurent Levy, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Alain Herrera
Dr. Alain Herrera
Independent Director
Independent Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairwoman of the of the Board
Independent Vice Chairwoman of the of the Board
--
--
Mr. Enno Spillner
Mr. Enno Spillner
Independent Director
Independent Director
--
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Bart Van Rhijn
Mr. Bart Van Rhijn
Chief Financial & Business Officer
Chief Financial & Business Officer
--
--
Ms. Anne-Juliette Hermant
Ms. Anne-Juliette Hermant
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Louis Kayitalire, M.D.
Dr. Louis Kayitalire, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Craig West
Mr. Craig West
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Ms. Anne-Sophie Lariviere
Ms. Anne-Sophie Lariviere
Vice President - Strategy & Operational Excellence
Vice President - Strategy & Operational Excellence
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Laurent Levy, Ph.D.
Dr. Laurent Levy, Ph.D.
Chief Executive Officer
Chief Executive Officer
--
--
Dr. Alain Herrera
Dr. Alain Herrera
Independent Director
Independent Director
--
--
Ms. Anne-Marie Graffin
Ms. Anne-Marie Graffin
Independent Vice Chairwoman of the of the Board
Independent Vice Chairwoman of the of the Board
--
--
Mr. Enno Spillner
Mr. Enno Spillner
Independent Director
Independent Director
--
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Bart Van Rhijn
Mr. Bart Van Rhijn
Chief Financial & Business Officer
Chief Financial & Business Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Jan 6
Updated: Tue, Jan 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Johnson & Johnson Innovation-JJDC, Inc.
11.66%
Geode Capital Management, L.L.C.
0.02%
Optiver Holding B.V.
0.01%
Other
88.30%
Shareholders
Shareholders
Proportion
Johnson & Johnson Innovation-JJDC, Inc.
11.66%
Geode Capital Management, L.L.C.
0.02%
Optiver Holding B.V.
0.01%
Other
88.30%
Shareholder Types
Shareholders
Proportion
Venture Capital
11.66%
Investment Advisor/Hedge Fund
0.02%
Investment Advisor
0.02%
Other
88.30%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
26
5.64M
11.71%
-3.12M
2025Q3
27
5.65M
11.71%
-4.13M
2025Q2
25
5.76M
12.15%
-4.19M
2025Q1
25
5.76M
12.15%
-4.19M
2024Q4
25
6.07M
12.79%
-4.24M
2024Q3
21
6.42M
13.54%
-3.89M
2024Q2
22
9.30M
19.73%
-1.04M
2024Q1
21
9.31M
19.76%
-988.94K
2023Q4
21
9.28M
19.68%
+1.01M
2023Q3
16
4.47M
12.36%
+481.67K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Johnson & Johnson Innovation-JJDC, Inc.
5.62M
11.66%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
10.18K
0.02%
--
--
Sep 30, 2025
Optiver Holding B.V.
5.36K
0.01%
+5.36K
--
Sep 30, 2025
Morgan Stanley & Co. International Plc
2.38K
0%
-2.92K
-55.13%
Sep 30, 2025
UBS Financial Services, Inc.
2.16K
0%
-2.26K
-51.09%
Sep 30, 2025
EverSource Wealth Advisors, LLC
514.00
0%
-3.00
-0.58%
Sep 30, 2025
BNP Paribas Securities Corp. North America
400.00
0%
-361.00
-47.44%
Sep 30, 2025
GAMMA Investing LLC
229.00
0%
+229.00
--
Dec 31, 2025
RBC Capital Markets Wealth Management
125.00
0%
--
--
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
33.00
0%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Biotechnology ETF
0%
iShares Biotechnology ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
